New Binding Sites for JAK2 Inhibition in Myeloproliferative Neoplasms: Structural Insights, Therapeutic Potential, and Future Directions.
New molecular targets on a key cancer protein could enable development of next-generation drugs to overcome resistance in myeloproliferative blood cancers.
This review identifies new druggable binding sites on JAK2 beyond the standard ATP-binding pocket in myeloproliferative neoplasms. These structural insights could enable development of next-generation inhibitors that overcome resistance to current therapies like ruxolitinib.
What the study was
- Study design
- Structural biology / drug discovery review
- Population
- MPN patients (conceptual)
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- ChemMedChem
Why it surfaced
Novel JAK2 binding site discovery relevant to MPN therapeutics. Review format limits evidence maturity.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.